• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Galen Institute

A not-for-profit health and tax policy research organization.

  • Home
  • About Us
    • Mission and History
    • Officers and Trustees
    • Scholars and Staff
    • Who was Galen?
  • Activities
    • Core Activities
    • State Leaders Calls
    • Commentary and Oped Tutorial
    • Our Book
    • Galen Guides
  • Donate
  • Contact Us

Prescription Drugs

Rebates And Drug Costs: What The New Proposal Would Mean

POSTED BY Grace-Marie Turner on February 28, 2019.

The Trump administration is trying in myriad ways to answer demands from consumers for lower prescription drug prices—a topic that got serious attention before the Senate Finance Committee on Tuesday where top executives of seven major drug companies testified. The president announced his “American Patients First” agenda in May, offering nearly 30 policy recommendations to … [Read more...] about Rebates And Drug Costs: What The New Proposal Would Mean

Filed Under: Forbes, Grace-Marie Turner, Prescription Drugs

Trump’s Misguided Solution to Drug Prices

POSTED BY RealClear Health on December 2, 2018.

The Trump administration has made important progress in loosening the federal government’s grip on private health insurance, freeing up more options for affordable health insurance. But the administration has veered off this free-market track with its  recent proposal to, among other things, slap a form of imported price controls on a specific class of prescription drugs in Medicare. To its … [Read more...] about Trump’s Misguided Solution to Drug Prices

Filed Under: Prescription Drugs

Amgen Announces Major Price Cut For Its Breakthrough Cholesterol Drug

POSTED BY Forbes on October 24, 2018.

By Grace-Marie Turner— The Trump administration continues to work overtime to lower prescription drug costs for consumers.  In response, some pharmaceutical companies have announced rollbacks of price increases, cuts in prices, price freezes, or other ways to improve affordability for patients. In the latest example, Amgen, a leading biologics company, is stepping forward to bring down prices … [Read more...] about Amgen Announces Major Price Cut For Its Breakthrough Cholesterol Drug

Filed Under: Innovation, Prescription Drugs

Save The Safety Net Drug Program For Patients Who Need Help

POSTED BY Grace-Marie Turner | Forbes on July 20, 2018.

A poster on the side of a bus stop in downtown Washington D.C. read: “Let 340B,” clearly a sign of an organized campaign asking Congress not to interfere with the gravy train for some hospital systems that this obscure provision has become. The safety net drug program, usually referred to as 340B for the section authorizing it in the Public Health Service Act, was created by Congress in 1992 to … [Read more...] about Save The Safety Net Drug Program For Patients Who Need Help

Filed Under: Medicaid, Prescription Drugs

A Surgical Approach To High Prescription Drug Prices

POSTED BY Grace-Marie Turner | Forbes on June 4, 2018.

President Trump’s plan to lower prescription drug costs uses a surgeon’s scalpel to address a range of issues, offering nearly 30 policy recommendations to modernize payment policies, weed out counter-productive regulations, improve price transparency, and expand competitive price negotiations. The plan reflects the complexity of the industry and the regulatory system that governs government … [Read more...] about A Surgical Approach To High Prescription Drug Prices

Filed Under: Medicare, Prescription Drugs

« Previous Page
Next Page »

Primary Sidebar

Categories

  • Brian Blase
  • Consumer-Directed Care
  • Doug Badger
  • Grace-Marie Turner
  • Health Insurance
  • Health Savings Accounts
  • Innovation
  • Medicaid
  • Medicare
  • Newsletter
  • ObamaCare
  • Prescription Drugs
  • Published
    • Forbes
    • LA Times
    • National Review
    • New York Post
    • RealClearHealth
    • The Daily Signal
    • The New York Times
    • The Wall Street Journal
  • Reform Initiatives
  • State Issues
  • Uncategorized

LATEST NEWSLETTER ISSUES

SUBSCRIBE

Social Media

Like Us On Facebook

Twitter: @galeninstitute

 

Copyright Galen Institute, Inc © 2019; · Log in